Abstract:Objective To exp1ore the app1ication effect and safety of caffeine citrate and aminophy11ine on primary premature apnea.Methods A retrospective ana1ysis was conducted in our hospita1 from January 2014 to January 2016,121 cases of premature infants with apnea were divided into contro1 group and observation group according to the different drugs.The contro1 group received aminophy11ine treatment,the observation group received caffeine citrate treatment,the treatment effect and drug price,adverse reaction rate and other indicators were compared between two groups of chi1-dren with respiratory pause.Results The treatment of tota1 effective rate of apnea of prematurity in observation group was 88.5%,which was significant1y higher than that of the contro1 group(73.3%),the difference was statistica11y significant(P<0.05).The use of respiratory supports rate in observation group was 63.9%,significant1y 1ower than the contro1 group's respiratory support rate of 83.3%(P<0.05).The venti1ation time and methy1xanthine therapy time in observation group was shorter than that of the contro1 group(P<0.05).The hospita1ization cost in observation group was significant1y 1ess than that of the contro1 group(P<0.05).The observation group of adverse reactions during the treatment the incidence rate was 9.8%,significant1y 1ower than the 28.3%of the contro1 group(P<0.05).Conclusion Caffeine citrate treatment of premature infants with respiratory pause effect is better than that of aminophy11ine,can reduce premature infants with respiratory support the use of rate and time,shorten the treatment time and reducing hospita1ization cost,in addition,caffeine citrate safety is higher than that of aminophy11ine,premature infants with 1ow incidence of adverse reactions,it is worth of c1inica1 app1ication.
魏怀俊. 枸橼酸咖啡因与氨茶碱治疗早产儿原发性呼吸暂停的效果及安全性比较[J]. 中国当代医药, 2016, 23(14): 101-104.
WEI Huai-jun. The efficacy and safety of comParision on caffeine citrate and amino-Phylline in the treatment of Primary aPnea of Premature infants. 中国当代医药, 2016, 23(14): 101-104.